Status:
UNKNOWN
Sevoflurane and Success of External Cephalic Version (ECV)
Lead Sponsor:
King Saud University
Conditions:
Version of Uterus
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
External cephalic version (ECV) is noninvasive procedure aiming to turn the fetus to cephalic presentation, thereby enabling vaginal delivery and avoiding unnecessary cesarean delivery. The American C...
Detailed Description
Pre- procedure all parturients will be asked to be fasting for 8 hours for solid and 2 hours for clear liquids. Before ECV (as routinely done in ECV procedure), a cardiotocogram (CTG) and obstetric ul...
Eligibility Criteria
Inclusion
- Patients \> 18 years old
- ASA status I or II (healthy women or patient with mild well-controlled systemic disease)
- Elective ECV
- 36 to 40 weeks of gestation
Exclusion
- Multifetal gestation
- Morbid obesity (BMI \> 40 at first prenatal medical visit)
- Oligohydramnios or polyhydramnios (AFI \<5 cm or \> 23 cm)
- Fetal weight \>4200g
- Active labor
- Uterine tumors or anomalies
- Abnormal placentation such as Placenta accreta/Previa
- Placental abruption
- Intrauterine fetal death
- Known allergy to sevoflurane
- History of malignant hyperthermia
- Administration of any tocolytics before or during ECV
Key Trial Info
Start Date :
May 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04346823
Start Date
May 25 2020
End Date
October 30 2021
Last Update
April 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.